Newron Pharmaceuticals bets big on Evenamide despite €13.2M loss in 2025

Newron Pharmaceuticals faced a challenging 2025, with financial losses and shifting revenue streams. The company reported a net loss of €13.2 million, a sharp turnaround from the previous year's €15.8 million profit. Despite this, it pushed ahead with key drug trials and secured fresh funding in early 2026 to support its growth plans. The company's financial struggles became clear as licensing revenue dropped from €51.4 million in 2024 to €19.1 million in 2025. Even so, Newron continued investing in research, spending €15.1 million on development in 2025. By the end of the year, its available liquidity stood at €28.9 million.

In February 2026, Newron raised up to €38 million through a capital increase, boosting its financial position. The funds arrived as its flagship drug, Evenamide, progressed in clinical trials. The Phase III ENIGMA-TRS program, split into two studies, began enrolling patients in August 2025 (ENIGMA-TRS 1, with at least 600 participants) and December 2025 (ENIGMA-TRS 2, with at least 400 participants). Meanwhile, EA Pharma started its own Phase III trial for Evenamide in Japan in January 2026.

Looking ahead, Newron's shareholders will vote on April 23, 2026, on statutory changes needed for a potential dual listing on the NYSE or Nasdaq. To qualify, the company must meet strict criteria, including a minimum share price of $1.00, sufficient market capitalisation, and strong US investor interest. Recent examples, such as InflaRx's compliance issues, highlight the importance of meeting these standards. Newron's 2025 results show a company in transition, balancing financial pressures with progress in drug development. The capital raise and ongoing trials for Evenamide provide a foundation for its next steps, including a possible US listing. Shareholders' upcoming vote will determine whether the company moves forward with its expansion plans.